Peter Zerhouni has been named the new CEO of InDex Pharmaceuticals and is scheduled to take office April 1. He will succeed Jesper Wiklund, who has led the company since 2011.

Wiklund has decided to leave InDex Pharmaceuticals to serve as Managing Director Europe at Oberland Capital, a life science focused investment firm based in the United States.

Since 2011,  Zerhouni has been the CEO of the publicly listed life science company Diamyd Medical AB, where he also was head of Business Development. He was a driving force behind one of the largest biotech out-licensing deals in Sweden in 2010. Zerhouni previously held various positions at ING Bank in Brussels and Amsterdam.

“We are very happy that Peter Zerhouni, with his long experience in developing life science companies from both a scientific and commercial perspective, will take over as CEO”, said Dr. Wenche Rolfsen, chairman of InDex Pharmaceuticals

At the next annual general meeting, Wiklund will be nominated as a new member of InDex Pharmaceuticals’ Board of Directors.

Source: InDex Pharmaceuticals